Dr. Hong Ge 葛红
Chief Physician
Department of Radiation Oncology, Henan Cancer Hospital, Zhengzhou
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Radiation therapy for malignant tumors, especially esophageal cancer, lung cancer, and mediastinal tumors. Specializes in stereotactic radiotherapy and comprehensive treatment for lung cancer.
Dr. Ge is a Chief Physician and Master’s supervisor at Henan Cancer Hospital. Roles include Deputy Director of the Henan Radiotherapy Center and Henan Lung Cancer Diagnosis and Treatment Center. Recognized as a State Council special allowance expert. Leads multiple research projects, including National Natural Science Foundation grants. Has received provincial science and technology progress awards and holds two national patents.
Professional roles
- Member, Youth Committee of Radiation Oncology Professional Committee, China Anti-Cancer Association
- Standing Committee Member, Radiation Oncology Professional Committee, Henan Medical Association
- Vice Chair, Minimally Invasive Professional Committee, Henan Anti-Cancer Association
- Reviewer, International Journal of Radiation Oncology Biology Physics
Name order: in Chinese the family name comes first (Ge Hong). Papers usually list the name as Hong Ge or Ge H.
Selected publications
139 papers on PubMed matched by name and affiliation; 73 as first or senior author since 2016. Most recent first- or senior-author papers:
- J Natl Cancer Inst, 2026 (senior author): RE: Health-related quality of life in patients with newly diagnosed advanced ovarian cancer receiving maintenance olaparib plus bevacizumab (PAOLA-1/ENGOT-ov25). PubMed 42377274
- Precis Radiat Oncol, 2026 (senior author): Expert consensus on clinical trial design guidelines for FLASH radiotherapy. PubMed 42780699
- J Thorac Oncol, 2026 (senior author): Letter to the Editor Regarding "Datopotamab Deruxtecan Plus Pembrolizumab With or Without Platinum-Based Chemotherapy for Advanced or Metastatic NSCLC: The Phase Ib TROPION-Lung02 Trial". PubMed 42697616
- J Natl Cancer Inst, 2026 (senior author): RE: Clinician- and facility-level factors associated with chemotherapy dose reductions in stages I-IIIA breast cancer. PubMed 42155041
- Precis Radiat Oncol, 2026 (senior author): One-year follow-up after fractionated ultra-high-dose-rate FLASH radiotherapy in patient with extramammary Paget disease of the scrotum. PubMed 42358284
- Front Oncol, 2026 (senior author): Quantifying statistical cure in unresectable locally advanced esophageal squamous cell carcinoma treated with radiotherapy-based regimens: a cure model analysis with SEER validation. PubMed 41971439
- Precis Radiat Oncol, 2026 (senior author): Segmentation influence on the generalizability of the overall survival models in CT-based oropharyngeal carcinoma patients. PubMed 42022350
- Clin Sci (Lond), 2026 (senior author): Evaluation of inflammation-mediated cancer progression during FLASH and conventional irradiation-induced lung injury. PubMed 41552931
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that most papers list this doctor's hospital and department.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion